Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07730567) titled 'A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-236A and AD-236B' on July 23.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Addpharma Inc.
Condition:
Hyperlipidemia
Diabete Type 2
Intervention:
Drug: Treatment A(AD-236A)
Drug: Treatment B(AD-236B)
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: July 29, 2026
Target Sample Size: 44
Countries of Recruitment:
South Korea
To know more, visit https://clinicaltrials.gov/s...